肿瘤患者外周血中抑制性受体LAIR-1表达升高

目的:研究LAIR-1在肿瘤患者中的表达,探讨其在抗肿瘤免疫应答中的作用.方法:应用夹心ELISA检测肿瘤患者血清中可溶型sLAIR-1的水平;应用免疫荧光染色和流式细胞术分析,观察LAIR-1在患者PBMC中NK细胞、CD4 T细胞、CD8 T细胞和B细胞上的表达.结果:肿瘤患者血清sLAIR-1水平为(4.6±3.2) μg/ L,明显高于正常人血清sLAIR-1 水平(3.9±3.0) μg/L,P<0.05.NK细胞,CD4 T细胞及CD8 T细胞表达LAIR-1水平上调.肺癌患者CD4/CD8比值明显低于正常人,B细胞百分率明显高于正常人.NK细胞、CD4 T细胞CD8 T细胞中LAIR-1的表达阳性率高于对照组.结论:在肿瘤患者LAIR-1分子表达水平高于正常人.肿瘤患者抑制性受体LAIR-1 表达水平的上调可能与肿瘤的免疫逃逸有关.

The up-regulated expression of LAIR-1 in tumor patients PBMC

AIM: To investigate the expression of LAIR-1 in patients with tumors and the function of LAIR-1 in anticancer immunity. METHODS: A sandwich ELISA was employed to detect the serum sLAIR-1 from tumor patients and healthy individuals. The expression of LAIR-1 in CD4(+) T cells, CD8(+) T cells, NK cells and B cells isolated from the peripheral blood of cancer patients was examined by fluorescence staining and flow cytometry. RESULTS: The level of serum sLAIR-1 in tumor patients was higher than that in heatlhy individuals 4.6+/-3.2 mug/L vs 3.9+/-3.0 mug/L, P<0.05]. NK cells, CD4(+) T cells and CD8(+) T cells expressed the up-regulated LAIR-1. The ratio of CD4/CD8 in lung cancer patients decreased significantly while the percentage of B cells in cancer patients increased greatly compared with healthy individuals. CONCLUSION: The expression of LAIR-1 is up-regulated in tumor patients, which may contribute to cancer immune escape.